Because CD9 is a pleiotropic protein that adversely affects the prognosis in patients with cancer [22,23], including intercellular communication in the immune system [24], it is possible that using the native form of CD9 as an EV tag can cause unexpected impacts in vivo. This evidence concerns the gene CD9 and cancer.